Chest
-
Non-Invasive VentilationSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: Our objective is to investigate the outcome of HMV in ≥ 75 years to determine if there are differences respect to younger patients. ⋯ The following authors have nothing to disclose: María del Carmen García García, Jacinto Hernández Borge, Pedro Pires Goncalves, Estefanía Molina Ortiz, Pilar Cordero Montero, María Teresa Gómez Vizcaíno, Francisca Lourdes Márquez Pérez, José Antonio Marín Torrado, Ana Castañar Jover, Ignacio Rodríguez BlancoNo Product/Research Disclosure Information.
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The etiology of bronchiectasis is varied with abnormal host defenses being one of the causes. We report the case of a 49-year-old male presenting with recurrent pneumonias. Imaging studies revealed bronchiectasis. Work up for bronchiectasis showed low immunoglobulin levels consistent with common variable immunodeficiency (CVID). The aim of this case report is to heighten awareness among physicians for the possibility of immunoglobulin deficiency in patients presenting especially with bronchiectasis, recurrent infections and sinus disease. ⋯ Among the various etiologies of bronchiectasis, the potentially treatable ones like CVID should never be missed. Appropriate and early institution of treatment can potentially improve survival, prevent deterioration of lung function and improve quality of life.Reference #1: Busse PJ, Farzan S, Cunningham-Rundles C, "Pulmonary complications of common variable immunodeficiency" Ann Allergy Asthma Immunol. 2007;98(1):1Reference #2: Park JH, Levinson AI,"Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)" Clin Immunol. 2010;134(2):97DISCLOSURE: The following authors have nothing to disclose: Khalid Sherani, Hineshkumar Upadhyay, Abhay Vakil, Kelly Cervellione, Craig ThurmNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Limited data are available regarding the validation of the European respiratory society (ERS) guidelines recommendations in patients with acute exacerbations of COPD (AECOPD).The ERS use an A3 recommendation to consider Pseudomonas aeruginosa (PA) in the presence of at least two PA risk factors. Our aim was to validate the ERS PA risk factors recommendation among patients hospitalized with an AECOPD. ⋯ The following authors have nothing to disclose: Pedro Marcos, Pilar Sanjuan, Marina Blanco-Aparicio, Jorge Ricoy, Isabel Otero, Hector Verea, Marcos RestrepoNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Exacerbations are the most frequent cause of hospitalization and death among patients with COPD. Combinations of long-acting bronchodilators maximize bronchodilation and may reduce the risk of exacerbations. QVA149, a once-daily dual bronchodilator containing the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium, improves lung function, breathlessness and rescue medication use compared with twice-daily salmeterol/fluticasone combination (SFC), in patients with moderate-to-severe COPD.1METHODS: In this 26-week, multicenter, double-blind study, patients ≥ 40 years with COPD (forced expiratory volume in 1 second [FEV1] ≥40% to <80% predicted and no history of exacerbations in the previous year) were randomized (1:1) to QVA149 110/50 µg or SFC 50/500 µg. In this post hoc analysis, we report the rate of mild, moderate or severe COPD exacerbations during 26 weeks of treatment with QVA149 or SFC. ⋯ Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Prof Eric Bateman has served on advisory boards for Boehringer Ingelheim, AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, and Merck and Takeda; has served as a consultant to Navigant Consulting, IMS consulting group, ALK-Abello, Almirall, Hoffman la Roche, and ICON; has been paid lecture fees by AstraZeneca, ALK-Abello, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Nycomed/Takeda, Novartis, Pfizer, and Indegene Lifesciences Ltd. Claus Vogelmeier: Consultant fee, speaker bureau, advisory committee, etc.: AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Janssen, Novartis, Pfizer, Almirall, Takeda, and Sterna Biologicals; has been paid lecture fees by AstraZeneca, Chiesi, GlaxoSmithKline, Janssen, Talecris, Novartis, Boehringer Ingelheim, Takeda, and Pfizer. Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Asthma Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: We present a 52 year old patient masquerading as a "difficult to control asthmatic". Her ultimate diagnosis is common variable immunodeficiency complicated by recurrent pulmonary infections, follicular bronchitis, and organizing pneumonia. This diagnosis is rare, but should be entertained in our patient's age group. The common variable immunodeficiencies (CVID) are relatively frequently encountered syndromes of various types of B-cell activation or differentiation defects, most often diagnosed during late childhood or early adult life. (1-4) Clinical manifestations of CVID include recurrent infections of the respiratory tract and, less frequently, autoimmune, granulomatous, or lymphoproliferative disorders. ⋯ The following authors have nothing to disclose: Susan Mucha, Mark Lega, Marvin BalaanNo Product/Research Disclosure Information.